1-[(4-CHLOROPHENYL)METHYL]-3-ETHYL-2,1,3-BENZOTHIADIAZIN-4-ONE-2,2-DIOXIDE
Compound with spectra: 1 NMR
![1-[(4-CHLOROPHENYL)METHYL]-3-ETHYL-2,1,3-BENZOTHIADIAZIN-4-ONE-2,2-DIOXIDE](/api/compound/BlQ1ywkKAUv.png?ph=true&h=300&w=458 "1-[(4-CHLOROPHENYL)METHYL]-3-ETHYL-2,1,3-BENZOTHIADIAZIN-4-ONE-2,2-DIOXIDE")
| SpectraBase Compound ID | BlQ1ywkKAUv |
|---|---|
| InChI | InChI=1S/C16H15ClN2O3S/c1-2-18-16(20)14-5-3-4-6-15(14)19(23(18,21)22)11-12-7-9-13(17)10-8-12/h3-10H,2,11H2,1H3 |
| InChIKey | HORMCYCRRFAFAU-UHFFFAOYSA-N |
| Mol Weight | 350.82 g/mol |
| Molecular Formula | C16H15ClN2O3S |
| Exact Mass | 350.049191 g/mol |
| Copyright | Copyright © 2016-2024 W. Robien, Inst. of Org. Chem., Univ. of Vienna. All Rights Reserved. |
|---|---|
| Solvent | CDCl3 |
1-BUTYL-3-ISOPROPYL-1H-2,1,3-BENZOTHIADIAZIN-(4)-3H-ONE 2,2-DIOXIDE
1H-2,1,3-Benzothiadiazin-4(3H)-one, 6-methoxy-1-methyl-3-(1-methylethyl)-, 2,2-dioxide
Anthranilic acid, N-(p-tolylsulfonyl)-N-veratryl-, methyl ester
1-[(3,4-DICHLOROPHENYL)MEHYL]-4(ETHYLOXY)-2,1,3-BENZOTHIADIAZINE-2,2-DIOXIDE
4-[(1-(4-chlorobenzyl)-2,4-dioxo-1,4-dihydro-3(2H)-quinazolinyl)methyl]-N-(4-methylbenzyl)benzamide
N-(2-chlorobenzyl)-5-(1-(4-chlorobenzyl)-2,4-dioxo-1,4-dihydro-3(2H)-quinazolinyl)pentanamide
N-(2-chlorobenzyl)-4-(1-(4-chlorobenzyl)-2,4-dioxo-1,4-dihydro-3(2H)-quinazolinyl)butanamide
N-(2-chlorobenzyl)-5-(1-(4-methylbenzyl)-2,4-dioxo-1,4-dihydro-3(2H)-quinazolinyl)pentanamide
1-(4-Biphenylylmethyl)-4-(4-biphenylylmethoxy)-2,1,3-benzothiadiazine 2,2-dioxide
2-(4-CHLOROPHENYL)-2,3,4,5-TETRAHYDRO-1-METHYLSULFONYL-2-PHENYL-1H-1,4-BENZODIAZEPIN-5-ONE
| Title | Journal or Book | Year |
|---|---|---|
| Benzothiadiazine dioxides (BTD) derivatives as non-nucleoside human cytomegalovirus (HCMV) inhibitors. study of structural requirements for biological activity☆ | Bioorganic & Medicinal Chemistry | 2003 |